AstraZeneca's tozorakimab achieved a third positive phase III trial result in treating chronic obstructive pulmonary disease (COPD), reinforcing its potential as a blockbuster drug. The MIRANDA trial demonstrated significant reductions in moderate-to-severe exacerbations across various patient groups, supporting Citi's $3.5 billion peak sales estimate, with potential upside from current smokers and high eosinophil patients. AstraZeneca projects peak sales between $3 billion and $5 billion, indicating room for growth beyond Citi's base case. Analysts noted a slight change in the trial announcement's tone but remain optimistic ahead of full data release.
AstraZeneca PLC will announce its Q2 2026 earnings on July 27, following a strong Q1 with 12.5% revenue growth to $15.29 billion. Key growth driver Enhertu saw a 39.4% year-over-year revenue increase, reaching $831 million, and recently gained EU app...
AstraZeneca has agreed to pay $600 million upfront and up to $1.5 billion total for global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer with a specific genetic mutation ...
AstraZeneca has agreed to pay $600 million upfront, with up to $900 million more based on milestones, to acquire global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer pati...
HSBC downgraded AstraZeneca from 'buy' to 'hold' following the failure of its Wainua phase III trial for a heart disease treatment, which missed its primary endpoint. This trial was a major part of HSBC's positive outlook, and its failure has led to ...
UBS maintains a 'buy' rating on AstraZeneca ahead of its Q2 results due on July 27, expecting solid performance but no increase in full-year guidance. The bank forecasts 2026 revenue of $63.3 billion and core earnings per share of $9.48, with a margi...
